Polynuclear neutrophils can play dual roles in sepsis: on the one hand they mediate major antimicrobial activities and on the other hand they can contribute to the development of multiple organ failure \[[@B1]\]. Nonetheless, in spite of the importance of these cells in sepsis, the influence of the circulating neutrophil count (CNC) on the prognosis of septic patients with this pathology has not been properly evaluated.

We analyzed the association between CNC and outcome in two cohorts of patients with diagnostic criteria of septic shock (SS) \[[@B2]\]: the first was recruited in the context of a single center study (EXPRESS study, discovery cohort, n = 195; Table [1](#T1){ref-type="table"}), and the second in the context of a multi-centric study (GRECIA study, validation cohort, n = 194; Table [2](#T2){ref-type="table"}). Written informed consent was obtained from each patient or their legal representative. The two studies were approved by the Research Ethics Committee of the Hospital Clínico Universitario, Valladolid, Spain (for the EXPRESS study) and Hospital Universitario Río Hortega, Valladolid, Spain (coordinating center for the GRECIA study).

###### 

Clinical characteristics of the patients in the discovery study in survivors and non-survivors at 28 days

                                     **Total (n = 195)**   **Survivors (n = 125)**   **Non-survivors (n = 70)**   ***P***
  ---------------------------------- --------------------- ------------------------- ---------------------------- ---------
  **Patient details**                                                                                              
       Gender (male)                 125 (64.1%)           79 (63.2%)                46 (65.7%)                   NS
       Age (years)                   71.6 ± 11.1           70.2 ± 11.1               74.2 ± 10.7                  0.014
       Hypertension                  109 (55.9%)           71 (56.8%)                38 (54.3%)                   NS
       Cardiovascular disease        87 (44.6%)            54 (43.2%)                33 (47.1%)                   NS
       Cancer                        44 (22.5%)            21 (16.8%)                23 (32.8%)                   0.010
       COPD                          33 (16.9%)            24 (19.2%)                9 (12.8%)                    NS
       Diabetes                      31 (15.9%)            24 (19.2%)                7 (10%)                      NS
       Obesity                       32 (16.4%)            21 (16.8%)                11 (15.7%)                   NS
       Smoker                        27 (13.8%)            17 (13.6%)                10 (14.2%)                   NS
       Chronic renal failure         26 (13.3%)            15 (12.0%)                11 (15.7%)                   NS
       Alcohol abuse                 12 (6.1%)             8 (6.4%)                  4 (5.7%)                     NS
       Inmunosuppression             9 (4.6%)              5 (4.0%)                  4 (5.7%)                     NS
       Hepatic disease               6 (3.1%)              4 (3.2%)                  2 (2.8%)                     NS
  **Clinical status at admission**                                                                                 
       APACHE II                     14.7 ± 5.9            13.9 ± 5.8                16.2 ± 5.9                   0.013
       Mechanical ventilation        134 (68.7%)           83 (66.4%)                51 (72.9%)                   NS
       OARF                          41 (21.0%)            19 (15.2%)                22 (31.4%)                   0.008
  **Presumed source of infection**                                                                                 
       Digestive system              115 (58.9%)           76 (60.8%)                39 (55.7%)                   NS
       Respiratory system            19 (9.7%)             14 (11.2%)                5 (7.1%)                     NS
       Central nervous system        20 (10.2%)            14 (11.2%)                6 (8.5%)                     NS
       Urinary system                10 (5.1%)             5 (4.0%)                  5 (7.1%)                     NS
       Endocardium                   7 (3.5%)              5 (4.0%)                  2 (2.8%)                     NS
       Catheter                      34 (17.4%)            26 (20.8%)                8 (11.4%)                    NS
       Wound/skin, soft tissue       28 (14.3%)            20 (16.0%)                8 (11.4%)                    NS
       Other/unknown                 55 (28.2%)            35 (28.0%)                20 (28.5%)                   NS
  **Type of surgery**                                                                                              
       Abdominal                     99 (50.7%)            56 (44.8%)                43 (61.4%)                   0.030
       Cardiac                       71 (36.4%)            54 (43.2%)                17 (24.3%)                   
       Other                         25 (12.8%)            15 (12.0%)                10 (14.3%)                   
  **Urgent surgery**                                                                                               
       Yes                           130 (66.6%)           77 (61.6)%                53 (75.7%)                   0.045
  **Documented microbial agent**                                                                                   
       Gram-negative                 67 (41.6%)            48 (44.4%)                19 (35.8%)                   NS
       Gram-positive                 68 (42.2%)            47 (43.5%)                21 (39.6%)                   NS
       Fungi                         24 (14.9%)            16 (14.8%)                8 (15.1%)                    NS
  **Laboratory data**                                                                                              
       Bilirubin (mg/dL)             1.4 ± 1.3             1.5 ± 1.4                 1.2 ± 1.0                    NS
       Glycemia (mg/dL)              166.4 ± 65.1          165.4 ± 58.3              168.2 ± 76.0                 NS
       Procalcitonin (ng/mL)         19.3 ± 32.5           16.5 ± 28.6               24.3 ± 38.1                  NS
       CRP (mg/mL)                   231.8 ± 119.2         221.9 ± 106.6             249.4 ± 138.1                NS
       INR                           1.7 ± 0.9             1.6 ± 0.9                 1.7 ± 0.8                    NS
       Platelets (×10^3^/μl)         190.2 ± 140.0         196.9 ± 143.5             178.2 ± 133.5                NS
       Leukocytes (×10^3^/μl)        16.3 ± 10.1           16.4 ± 9.0                16.2 ± 11.7                  NS
       Monocytes (×10^3^/μl)         0.7 ± 0.4             0.7 ± 0.4                 0.6 ± 0.5                    NS
       Lymphocyte (×10^3^/μl)        1.1 ± 0.7             1.1 ± 0.8                 1.0 ± 0.6                    NS
       Neutrophils (×10^3^/μl)       14.4 ± 9.4            14.4 ± 8.4                14.3 ± 11.1                  NS
       Basophils (×10^3^/μl)         0.1 ± 0.0             0.1 ± 0.1                 0.1 ± 0.0                    NS
       Eosinophils (×10^3^/μl)       0.1 ± 0.0             0.1 ± 0.0                 0.1 ± 0.0                    NS

For the demographic characteristics of the patients, differences between groups were assessed using the χ2 test for categorical variables and the Student\'s *t*-test for continuous variables when appropriate. Continuous variables are expressed as mean ± standard deviation. APACHE, Acute Physiology and Chronic Health Evaluation; COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; INR, international normalized ratio; NS, not significant; OARF, oliguric acute renal failure.

###### 

C**linical characteristics of the patients in the validation study in survivors and non-survivors at 28 days**

                                     **Total (n = 194)**   **Survivors (n = 132)**   **Non-survivors (n = 62)**   ***P***
  ---------------------------------- --------------------- ------------------------- ---------------------------- ---------
  **Patient details**                                                                                              
       Gender (male)                 126 (64.9%)           85 (64.3%)                41 (66.1%)                   NS
       Age (years)                   67.1 ± 13.3           65.3 ± 14.3               71.1 ± 9.5                   \<0.001
       Inmunosuppression             35 (18.0%)            15 (11.3%)                20 (32.2%)                   \<0.001
       Diabetes                      32 (16.4%)            21 (15.9%)                11 (17.7%)                   NS
       Cardiovascular disease        24 (12.3%)            14 (10.6%)                10 (16.1%)                   NS
       Cancer                        18 (9.2%)             10 (7.5%)                 8 (12.9%)                    NS
       COPD                          23 (11.8%)            12 (9.0%)                 11 (17.7%)                   NS
       Chronic renal failure         15 (7.7%)             10 (7.5%)                 5 (8.0%)                     NS
       Alcohol abuse                 12 (6.1%)             7 (5.3%)                  5 (8.0%)                     NS
       Hepatic disease               4 (2.0%)              1 (0.7%)                  3 (4.8%)                     NS
  **Clinical status at admission**                                                                                 
       APACHE II score               22.6 ± 7.0            21.0 ± 6.5                25.9 ± 7.1                   \<0.001
       Mechanical ventilation        150 (77.7%)           93 (70.9%)                57 (91.9%)                   \<0.001
       OARF                          39 (20.1%)            17 (12.8%)                22 (35.4%)                   \<0.001
  **Presumed source of infection**                                                                                 
       Respiratory system            67 (34.5%)            45 (34.1%)                22 (35.5%)                   NS
       Digestive system              52 (26.8%)            32 (24.2%)                20 (32.3%)                   NS
       Urinary system                26 (13.4%)            21 (15.9%)                5 (8.1%)                     NS
       Catheter                      16 (8.2%)             11 (8.3%)                 5 (8.1%)                     NS
       Wound/skin, soft tissue       15 (7.7%)             11 (8.3%)                 4 (6.5%)                     NS
       Other/unknown                 18 (9.3%)             12 (9.1%)                 6 (9.7%)                     NS
  **Documented microbial agent**                                                                                   
       Gram-negative                 52 (26.8%)            36 (27.2%)                16 (25.8%)                   NS
       Gram-positive                 33 (17.0%)            25 (18.9%)                8 (12.9%)                    NS
       Fungi                         12 (6.1%)             4 (3.0%)                  8 (12.9%)                    0.020
  **Laboratory data**                                                                                              
       Bilirubin (mg/dL)             1.4 ± 2.2             1.4 ± 2.1                 1.6 ± 2.4                    NS
       Glycemia (mg/dL)              168 ± 64.0            167 ± 62.4                172.0 ± 67.6                 NS
       INR                           1.8 ± 3.1             1.9 ± 3.8                 1.6 ± 0.6                    NS
       Platelets (×10^3^/μl)         177.4 ± 118.5         173.6 ± 105.2             186.4 ± 146.1                NS
       Leukocytes (×10^3^/μl)        18.0 ± 16.4           18.4 ± 17.0               17.3 ± 15.3                  NS
       Monocytes (×10^3^/μl)         0.7 ± 1.7             0.8 ± 20.2                0.6 ± 0.9                    NS
       Lymphocyte (×10^3^/μl)        1.8 ± 70.5            1.6 ± 73.5                2.3 ± 64.1                   NS
       Neutrophils (×10^3^/μl)       14.9 ± 12.5           15.6 ± 12.9               13.6 ± 11.5                  NS
       Basophils (×10^3^/μl)         0.1 ± 0.0             0.1 ± 0.0                 0.1 ± 0.0                    NS
       Eosinophils (×10^3^/μl)       0.1 ± 0.0             0.1 ± 0.0                 0.1 ± 0.0                    NS

For the demographic characteristics of the patients, differences between groups were assessed using the χ2 test for categorical variables and the Student\'s *t*-test for continuous variables when appropriate. Continuous variables are expressed as mean ± standard deviation. APACHE, Acute Physiology and Chronic Health Evaluation; COPD, chronic obstructive pulmonary disease; INR, international normalized ratio; NS, not significant; OARF, oliguric acute renal failure.

When patients of the discovery cohort were split based on deciles for CNC at SS diagnosis, those with CNC \<7,226 cells/mm^3^ (decile 2) died earlier than the other non-survivors (Figure [1](#F1){ref-type="fig"}). Multivariate Cox regression analysis showed that patients with CNC below this cutoff value had an almost two-fold risk of death (Figure [1](#F1){ref-type="fig"}). The cutoff value was evaluated again in the validation cohort, with similar results (Figure [1](#F1){ref-type="fig"}). Counts of other leukocyte subtypes had no significant association with outcome.

![**Impact of circulating neutrophil count on mortality: Kaplan-Meier survival curves.** Groups were compared by the log-rank test (Mantel- Haenzel). Bottom: multivariate Cox regression analysis for mortality risk. Circulating neutrophil count (CNC) was adjusted by age, sex and Acute Physiology and Chronic Health Evaluation II score. Time was censored at 28 days following diagnosis. CI, confidence interval; Cum, cumulative; HR, hazard ratio.](cc13728-1){#F1}

Although normal reference values in blood vary depending on sex, race and age, available literature supports that 7,226 cells/mm^3^ is at the upper limit of normal CNC values \[[@B3]\]. Patients with insufficient numbers of circulating neutrophils during the early stages of SS could have difficulties mounting effective innate responses against the invading microbe(s). Increased neutrophil adhesion to the vascular endothelium in sepsis could contribute to lower CNC. Neutrophils adhered to the blood vessel wall seem to induce endothelial damage \[[@B4]\], forming leukocyte aggregates that could lead to microvascular thrombosis \[[@B1],[@B5]\]. Host immunity compromise and/or increased endothelial damage could both impair outcome in these patients.

CNC at diagnosis is a major prognostic factor in SS. Our work provides a CNC cutoff that is potentially useful as a prognostic indicator.
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